2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

J Steffel, R Collins, M Antz, P Cornu, L Desteghe… - EP …, 2021 - academic.oup.com
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Diagnosis and treatment of acute coronary syndromes: a review

DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …

Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines

S Kietaibl, R Ferrandis, A Godier, J Llau… - European Journal of …, 2022 - journals.lww.com
BACKGROUND Bleeding is a potential complication after neuraxial and peripheral nerve
blocks. The risk is increased in patients on antiplatelet and anticoagulant drugs. This joint …

Antiplatelet therapy after percutaneous coronary intervention

DJ Angiolillo, M Galli, JP Collet, A Kastrati… - …, 2022 - pmc.ncbi.nlm.nih.gov
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic …

J Dawson, Y Béjot, LM Christensen… - European stroke …, 2022 - journals.sagepub.com
Recurrent stroke affects 9% to 15% of people within 1 year. This European Stroke
Organisation (ESO) guideline provides evidence-based recommendations on …

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …

J Knuuti, W Wijns, A Saraste, D Capodanno… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse …

SV Rao, B Kirsch, DL Bhatt, A Budaj, R Coppolecchia… - Circulation, 2022 - ahajournals.org
Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent
thromboembolic events without substantially increasing bleeding. We explored the …

Rivaroxaban in peripheral artery disease after revascularization

MP Bonaca, RM Bauersachs, SS Anand… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …